Rheumatoid arthritis drug safety and effectiveness registry
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This registry collects real-world information about people with rheumatoid arthritis (RA) to help doctors understand how RA medicines work and their safety. You may be able to join if you’re newly diagnosed or starting certain RA treatments and you’re willing to share consent and basic personal details.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older
- Have a rheumatologist-confirmed diagnosis of rheumatoid arthritis
- Be willing to sign consent and share basic identity details (name and date of birth)
- Be starting or currently taking an RA medicine that qualifies (or be newly diagnosed within the last year)
- Not have other specific autoimmune arthritis types (like psoriatic arthritis or lupus)
- Not be enrolled in a double-blind RA drug trial (other non-blind studies may be okay)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood or other samples from people with rheumatology (joint/autoimmune) conditions. It looks at changes around the time you start a specific new medicine, which may help researchers understand how treatments work.
This registry is collecting information about people with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis who are starting or needing biologic or targeted medicines. It may help researchers better understand how these treatments work in real life.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.